好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real-world Implementation of Blood Biomarkers – Updates from the Ongoing Global Accurate Diagnosis Project
Aging, Dementia, and Behavioral Neurology
P7 - Poster Session 7 (8:00 AM-9:00 AM)
12-010

This multi-site study aims to identify best practices, barriers, and facilitators for real-world implementation of Alzheimer’s disease (AD) blood biomarker (BBM) tests.
Timely and accurate AD diagnosis is essential for patients and families to access appropriate care, supportive services, and plan for the future. AD BBMs are promising innovations, but healthcare systems are not prepared to integrate them into routine practice. In 2024, the Davos Alzheimer’s Collaborative Healthcare System Preparedness (DAC-SP) program launched the Accurate Diagnosis project in eight sites across five countries, as the first global implementation study of BBM use in real-world primary and specialty care settings.

The DAC-SP Accurate Diagnosis project is a mixed-methods implementation study to evaluate process (e.g., acceptability, feasibility) and adoption outcomes (e.g., clinical and health services outcomes) of using BBMs in clinical practice. Sites developed independent protocols for implementing BBMs while contributing to a core dataset for cross-site quantitative analysis.  Surveys and qualitative interviews at baseline, midpoint, and post-program will be used to assess provider confidence and perceived utility of BBMs. DAC-SP convenes communities of practice to facilitate shared learnings and implementation strategies.
To date, 280 providers across 98 clinics have been trained on BBM pathways, and 1,872 BBM tests ordered. Implementation strategies facilitating BBM uptake include cross-departmental collaboration on workflow development, provider education, and creation of tools to support BBM integration and disclosure of results. Key learnings on BBM care pathway implementation, provider-reported confidence, and enrollment statistics will be reported. 
Successful BBM integration requires alignment with system technologies, clear communication strategies, and sustained provider support. Cross-site learnings will be disseminated through the  to support healthcare systems worldwide. Findings will inform broader BBM adoption so patients and families benefit from a timely and accurate AD diagnosis.
Authors/Disclosures
Amy Deckert, PhD
PRESENTER 		Dr. Deckert has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Davos Alzheimer's Collaborative.
Monica Zigman Suchsland, PhD Dr. Zigman Suchsland has received personal compensation in the range of $50,000-$99,999 for serving as a Consulting Epidemiologist with Davos Alzheimer's Collaborative.
Karen Weyrauch Ms. Weyrauch has received personal compensation in the range of $100,000-$499,999 for serving as a Project Manager with Davos Alzheimer's Collaborative.
Timothy MacLeod, PhD Dr. MacLeod has received personal compensation for serving as an employee of Davos Alzheimer's Collaborative.
Alissa Kurzman, MPH Ms. Kurzman has received personal compensation in the range of $50,000-$99,999 for serving as a Program Lead, Learning Laboratory with Davos Alzheimer's Collaborative.
Katie Selzler, PhD Dr. Selzler has stock in Eli Lilly. Dr. Selzler has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant with Davos Alzheimer's Collaborative.